Triple-helical transition state analogues: a new class of selective matrix metalloproteinase inhibitors.
about
A macrophage cell model for selective metalloproteinase inhibitor designCardiac transgenic matrix metalloproteinase-2 expression induces myxomatous valve degeneration: a potential model of mitral valve prolapse disease.Extracellular proteases as targets for drug developmentExosite interactions impact matrix metalloproteinase collagen specificities.New strategies for targeting matrix metalloproteinasesMatrix metalloproteinase inhibition by heterotrimeric triple-helical Peptide transition state analoguesTargeting invadopodia to block breast cancer metastasisMatrix metalloproteinases as breast cancer drivers and therapeutic targets.The history of matrix metalloproteinases: milestones, myths, and misperceptions.Synthesis of Fmoc-Gly-Ile Phosphinic Pseudodipeptide: Residue Specific Conditions for Construction of Matrix Metalloproteinase Inhibitor Building BlocksSynthesis of P,N-heterocycles from omega-amino-H-phosphinates: conformationally restricted alpha-amino acid analogsIdentification of specific hemopexin-like domain residues that facilitate matrix metalloproteinase collagenolytic activity.Synthesis and biological applications of collagen-model triple-helical peptides.Selective modulation of matrix metalloproteinase 9 (MMP-9) functions via exosite inhibition.Efficient synthesis of Fmoc-protected phosphinic pseudodipeptides: Building blocks for the synthesis of matrix metalloproteinase inhibitors.Therapeutic Potential of Matrix Metalloproteinase Inhibition in Breast Cancer.Functional characterization of selective exosite-binding inhibitors of matrix metalloproteinase-13 (MMP-13) - experimental validation in human breast and colon cancer.
P2860
Q33680972-F8982CDF-6D34-46E9-B4C7-C0342238BFD5Q34598006-F3C19EDA-52D3-46C4-9E4B-24614AE0E341Q35116202-77778FDF-A8F8-40E3-90D4-9D340552C3C1Q35423858-30B2C854-D866-4008-8F46-90205A159AC0Q35544060-AAF5D88A-2A0C-48B0-9E9A-938C6E55EB8BQ35557168-BD32156D-D723-4672-B206-A641D2D2925AQ35640216-814C16A4-7A78-4B96-AFAB-92C3FDF51E07Q35892721-0B0CDC8B-ED43-42A6-B11C-1402239390E7Q36312509-895C6A24-C446-4937-A3FF-D639C9896761Q36587992-ED7E5CFE-442D-400C-9D1D-55FE69888CD6Q37161115-A99C25D7-611C-4C9C-8B10-74C99F88BE5AQ37433262-461D67A4-D6EA-44E2-A74F-C2237350FB31Q37632930-3CB55D67-CDC0-4F3C-A108-1D12DBB7A1F0Q40089357-C64A8A38-530A-49E5-A2CD-9B920B105A3EQ42576327-8909D099-7812-425E-96D9-89E2ED9F9A81Q42720277-D6548BE7-C5BF-4133-9F44-3916452F39C3Q50790658-A4B5782F-1DDD-44C1-A069-D1530DB502E5
P2860
Triple-helical transition state analogues: a new class of selective matrix metalloproteinase inhibitors.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Triple-helical transition stat ...... metalloproteinase inhibitors.
@en
type
label
Triple-helical transition stat ...... metalloproteinase inhibitors.
@en
prefLabel
Triple-helical transition stat ...... metalloproteinase inhibitors.
@en
P2093
P2860
P356
P1476
Triple-helical transition stat ...... metalloproteinase inhibitors.
@en
P2093
Gregg B Fields
Janelle Lauer-Fields
John K Whitehead
Keith Brew
Robert P Hammer
P2860
P304
10408-10417
P356
10.1021/JA0715849
P407
P577
2007-08-02T00:00:00Z